Continuous manufacturing via hot-melt extrusion and scale up: regulatory matters

Maniruzzaman, Mohammed and Nokhodchi, Ali (2017) Continuous manufacturing via hot-melt extrusion and scale up: regulatory matters. Drug Discovery Today, 22 (2). pp. 340-351. ISSN 1359-6446

[img] PDF - Accepted Version
Download (472kB)

Abstract

Currently, because globalization, the pharmaceutical industry is facing enormous challenges to comply with regulatory matters. Reduced patent life and overall decreased profitability of newly discovered drugs are also forcing the pharmaceutical industry to shorten the drug development time with maximum throughput. Therefore, continuous manufacturing (CM) processes via hot melt extrusion (HME) can be a promising alternative for achieving these goals. HME offers solvent-free green technology with a process that is easy to scale up. Moreover, CM provides better product quality assurance compared with batch processes, with fewer labor costs and shorter time to development. In this review, we primarily focus on various aspects of CM and the emerging application of HME to bridge the current manufacturing gap in pharmaceutical sphere.

Item Type: Article
Schools and Departments: School of Life Sciences > Chemistry
Depositing User: Mohammed Maniruzzaman
Date Deposited: 17 Nov 2016 13:38
Last Modified: 17 Nov 2017 02:03
URI: http://sro.sussex.ac.uk/id/eprint/65524

View download statistics for this item

📧 Request an update